MAZE — Maze Therapeutics, Inc. stock price, charts and financials

Latest market price

26.97

-1.68-5.87%

Overview Short InterestFilings

MAZEQT65Maze Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

26.97-5.87%

Earnings

Down 5.9% — Earnings due 2026-08-11 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.33%$15.48 MESO+4.96%$16.73 ZBIO-1.46%$31.96 GHRS-2.07%$29.64 TSHA-0.69%$6.51 STOK-1.46%$32.23 ABCL+31.03%$9.08 VRDN-2.29%$23.05

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	13.64%	Shs Outstand	55.35M	Perf Week	6.43%

Market Cap	1.59B	Forward P/E	-	EPS next Y	-3.22	Insider Trans	-3.91%	Shs Float	15.98M	Perf Month	-11.63%

Enterprise Value	1.45B	PEG	0.01	EPS next Q	-	Inst Own	120.25%	Short Float	9.98%	Perf Quarter	12.49%

Income	-125.90M	P/S	79.28	EPS this Y	-	Inst Trans	-	Short Ratio	8.23	Perf Half Y	-34.81%

Sales	20.00M	P/B	4.52	EPS next Y	-17.96%	ROA	-29.20%	Short Interest	5.53M	Perf YTD	-30.85%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-36.63%	52W High	50.50 -46.60%	Perf Year	101.05%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-33.24%	52W Low	12.06 123.65%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	92.04%	Volatility	5.82% 5.48%	Perf 5Y	-

Dividend TTM	-	EV/Sales	72.40	EPS Y/Y TTM	-3351.93%	Oper. Margin	-670.25%	ATR (14)	1.55	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	17.88	Sales Y/Y TTM	-	Profit Margin	-612.71%	RSI (14)	53.14	Recom	1.86

Dividend Gr. 3/5Y	-	Current Ratio	17.88	EPS Q/Q	60.87%	SMA20	1.67%	Beta	1.04	Target Price	80.50

Payout	0.00%	Debt/Eq	0.18	Sales Q/Q	-	SMA50	4.34%	Rel Volume	0.84	Prev Close	28.65

Employees	141	LT Debt/Eq	0.05	Earnings	Aug 11	SMA200	-17.07%	Avg Volume	570.20K	Price	26.97

IPO Date	Jan 31, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.98% 88.24%	Net Debt/EBITDA	1.15	Volume	480,729	Change	-5.87%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Apr-14-26	Reiterated	Truist Securities	Buy	$68 → $64
Mar-17-26	Reiterated	Truist Financial		$68
Mar-10-26	Initiated	Mizuho	Outperform	$97
Jan-16-26	Reiterated	BTIG	Buy	$30 → $46
Dec-19-25	Reiterated	Guggenheim	Buy	$34 → $46
Dec-04-25	Initiated	Wells Fargo	Overweight	$55
Dec-03-25	Reiterated	HC Wainwright & Co.	Buy	$60
Nov-13-25	Initiated	Raymond James	Strong Buy	$48
Sep-15-25	Reiterated	Guggenheim	Buy	$34
Sep-02-25	Initiated	BTIG	Buy	$30

Latest News

Jul-21-26

Jul-21-2610:55AM

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?zacks.com

Jun-29-26

Jun-29-2608:46AM

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?fool.com

Company

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Ownership

Total institutional ownership120.25%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022
Total Revenue	0	168	0	—
Cost of Goods Sold Incl. D&A	2	0	0	—
Gross Profit	-2	168	0	—
Selling, General and Administrative Excl. Other	34	26	25	—
Research and Development	108	83	74	—
Other Operating Expense	-2	1	0	—
Operating Income	-143	58	-99	—
Interest Expense	0	0	0	—
Unusual Expense	—	—	—	—
Non-Operating Income (Expense)	12	-4	-2	—
Net Income Before Taxes	-131	53	-100	—
Income Taxes	0	1	0	—
Consolidated Net Income	-131	52	-100	—
Net Income From Continuing Operations	-131	52	-100	—
Net Income	-131	52	-100	—
EPS (Recurring)	-3.05	0.08	-2.29	—
EPS (Basic, Before Extraordinaries)	-3.05	0.08	-2.29	—
EPS (Diluted)	-3.05	0.08	-2.29	—
EBITDA	-129	57	-96	—
Other After Tax Adjustments	—	—	—	—
Stock Option Compensation Expense	—	—	—	—
Price To Earnings Ratio	—	—	—	—
Price To Sales Ratio	—	—	—	—
Gross Margin	—	100.00	—	—
Operating Margin	—	34.52	—	—
Net Margin	—	30.95	—	—
Shares Outstanding	43	44	44	—
Market Capitalization	1,781	—	—	—
Operating Lease Expense	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coloma Jason V	Chief Executive Officer	Aug 03 '26	Sale	26.73	34,501	922,315	20,744	Aug 05
Dandekar Atul	CSBO	Jul 29 '26	Sale	27.34	7,500	205,031	26,250	Jul 31
Dandekar Atul	CSBO	Jul 29 '26	Option Exercise	10.42	7,500	78,150	33,750	Jul 31
Bernstein Harold	President, R&D & CMO	Jul 01 '26	Sale	29.90	14,609	436,864	0	Jul 02
Coloma Jason V	Chief Executive Officer	Jul 01 '26	Sale	29.98	34,501	1,034,253	23,337	Jul 02
Bernstein Harold	President, R&D & CMO	Jul 01 '26	Option Exercise	10.42	14,609	152,226	14,609	Jul 02
Dandekar Atul	CSBO	Jun 29 '26	Sale	28.02	7,500	210,150	26,250	Jul 01
Dandekar Atul	CSBO	Jun 29 '26	Option Exercise	10.42	7,500	78,150	33,750	Jul 01
Coloma Jason V	Chief Executive Officer	Jun 23 '26	Sale	26.05	23,865	621,674	319,079	Jun 24
Coloma Jason V	Chief Executive Officer	Jun 22 '26	Sale	26.00	3,993	103,821	25,930	Jun 24
Bernstein Harold	President, R&D & CMO	Jun 01 '26	Sale	25.66	14,853	381,112	0	Jun 03
Bernstein Harold	President, R&D & CMO	Jun 01 '26	Option Exercise	10.42	14,853	154,768	14,853	Jun 03
Coloma Jason V	Chief Executive Officer	Jun 01 '26	Sale	26.20	6,643	174,048	27,970	Jun 03
Dandekar Atul	CSBO	May 29 '26	Option Exercise	10.42	7,500	78,150	32,308	Jun 02
Dandekar Atul	CSBO	May 29 '26	Sale	26.34	7,500	197,554	24,808	Jun 02

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.